Next-Generation Sequencing (NGS) Services (Single Cell Seq, Small RNA Seq) Markets, 2025 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Next-Generation
Sequencing (NGS) Services Market Size, Share & Trends Analysis Report By
Service Type (Single Cell Seq, Small RNA Seq), By Workflow, By End Use,
And Segment Forecasts, 2018 – 2025”
report has been added to ResearchAndMarkets.com’s
offering.

The global next-generation sequencing (NGS) services market size is
expected to reach USD 2.87 billion by 2025 at a 13.6% CAGR during the
forecast period.

Development of NGS technologies has revolutionized gene sequencing in
terms of reproducibility and cost savings.

This has resulted in introduction of several advancements in NGS
technology to promote its usage in clinical labs and hospitals. Most
current innovations in this field revolve around simplifying usage of
seq-technology and making it more sophisticated. These factors have
driven the uptake of NGS services across various end users.

Conventional disease testing service providers have broadened their
portfolio with a rising trend of seq-based genetic tests. For example,
in October 2014, ARUP Laboratories collaborated with the Children’s
Hospital of Philadelphia (CHOP). The service provision for NGS-based HLA
genotyping, including HLA Class II and HLA Class I, began in November
2017.

With rising trend of high throughput sequencing within the pharma and
biotech industry, there is a need for more developments to improve the
speed and convenience of high throughput seq-platforms and simplify
workflows. As a result, companies are focusing on development of
solutions to simplify the amplification and purification of sample and
starting input.

In July 2017, Norgen released the new Small RNA Library Prep Kit for
Illumina. This kit is being developed to generate small RNA libraries
and is optimized for samples with low input RNA (0.5-1ng), such as
urine, serum, plasma, cerebral spinal fluid (CSF), blood, and exosomes.

Further key findings from the report suggest:

  • Human genome sequencing services held the largest revenue share owing
    to greater penetration of whole genome and whole exome sequencing
  • Gene regulation services, particularly small RNA sequencing and
    ChIP-seq, is anticipated to grow at a lucrative pace during the
    forecast period. Rising investment in RNA sequencing is driving the
    growth of gene regulation services
  • Increase in installation of sequencing platforms is attributive to the
    larger revenue share of sequencing services as compared to other
    workflow steps. High maintenance and recovery costs of this step have
    also resulted in greater revenue generation
  • Universities and other research entities have emerged as prominent end
    users owing to growing application of NGS technology for cancer
    prognosis as well as diagnosis and major projects taken up by
    academicians and universities
  • North America dominated the market by revenue in 2017, owing to higher
    penetration of the technology in this region and availability of funds
    to employ the technique and derive research findings for disease
    targeting
  • Various prominent players in this market include Illumina, Inc.;
    Eurofins Genomics; BGI; and GENEWIZ Germany GmbH. Companies such as
    GENEWIZ and Novogene Corporation are engaged in offering NGS services
    based on platforms from major NGS developers
  • Companies such as Illumina and BGI, on the other hand, are involved in
    developing sequencing instruments and offering services to research
    entities.

For more information about this report visit https://www.researchandmarkets.com/r/c7iaep

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Molecular
Diagnostics